The first-ever patient in a Phase 3 medical study of LSD has successfully tripped balls

Biopharma firm Mind Medicine announced that they have dosed the first-ever patient in a Phase 3 clinical trial of LSD. The individual tripped on lysergide D-tartrate, an LSD formulation for which the US FDA granted "breakthrough therapy" status in March as a promising treatment for generalized anxiety disorder (GAD).

Of course, Mind Medicine has patented…